Needles can lead to various diseases, such as HIV, and injuries if not administered with proper precautions. According to the article “MEDICSEN: NEEDLE-FREE SMARTPATCH FOR PAINLESS DRUG DELIVERY’, over 2,000 people in the US are affected by needlestick injuries per day, generating over US$ 3 billion in associated costs every year. The use of needle-free drug delivery devices decreases the chances of these injuries and diseases. Thus, a surge in the prevalence of needlestick injuries and a rise in spending for treatment fuels the growth of the needle-free drug delivery devices market
Needle-free drug deliveries are taken in the form of power sprays, jet injectors, inhalers, and skin patches. Needle-free technology reduces patient concern about using needles. Needle-free devices are effective injections for a wide range of drugs and are bioequivalent to needles. Advantages of needle-free delivery devices include less pain, fast injection, no needle disposal issue, and can be self-administered. Thus, the benefits of needle-free drug delivery devices over conventional needles and syringes are mainly responsible for the increasing demand for needle-free drug delivery devices.
Chronic diseases such as heart disease, diabetes, and cancer are the leading causes of death and disability worldwide. As per the Centers for Disease Control and Prevention (CDC), ~38.4 million people in America were suffering from diabetes in 2021. To control the incidence of diabetes, insulin is injected through the subcutaneous layer at regular intervals. Due to an increase in the prevalence of diabetes, the demand for insulin injections is also growing. The companies are focusing on developing needle-free insulin devices to avoid needlestick injuries. For instance, Medicsen is focusing on developing SmartPatch to deliver insulin with more efficacy.
A shift from hospitals, long-term facilities, inpatient rehabilitation, and skilled nursing facilities to home care settings results in greater chances of better, consistent, and timely interaction between patient and doctor owing to the growing utilization of cloud and mobility-driven medical devices. In developing countries, the number of patients receiving home therapy has been limited in the past. The smart patches and jet injectors are integrated with electronic health records (EHR), allows doctors to monitor the dosage for anywhere. With the help of needle-free drug delivery devices, the patient can easily self-administer their drugs according to the requirements prescribed by the doctor. Thus, an increase in focus on home healthcare and the use of technologically integrated products is expected to act as an opportunity for growth of the market during the forecast period.
Key segments that contributed to the derivation of the needle-free drug delivery devices market analysis are type and application.
The geographic scope of the needle-free drug delivery devices market report is mainly segmented into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America.
North America dominated the needle-free drug delivery devices market in 2023. The market growth in North America is characterized by increased demand for rare disease medications from biopharmaceutical and biotechnology companies, the presence of key market players, an increase in product launches, a rise in the burden of needle stick injuries, and extensive R&D conducted by academic and research institutes and pharmaceutical and biotechnology companies. Moreover, Asia Pacific is anticipated to record the highest CAGR in the coming years.
The needle-free drug delivery devices market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for needle-free drug delivery devices and strategies:
The regional trends and factors influencing the Needle-Free Drug Delivery Devices Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Needle-Free Drug Delivery Devices Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
Report Attribute | Details |
---|---|
Market size in 2023 | US$ 14.76 Billion |
Market Size by 2031 | US$ 28.42 Billion |
Global CAGR (2023 - 2031) | 8.5% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
The Needle-Free Drug Delivery Devices Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Needle-Free Drug Delivery Devices Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The “Needle-Free Drug Delivery Devices Market Size and Forecast (2023–2031)” report provides a detailed analysis of the market covering below areas:
The List of Companies - Needle-Free Drug Delivery Devices Market
The needle-free drug delivery device market majorly consists of the players such NuGen Medical Devices Inc, NovaXS Biotech, GlaxoSmithKline, AstraZeneca, Roche, Boehringer Ingelheim, Merck, Cipla, Novartis, Teva Pharmaceuticals, Omron Healthcare, Sumitomo Pharma Co., Ltd
Needle-free drug deliveries are taken in the form of power sprays, jet injectors, inhalers, and skin patches. Needle-free technology reduces patient concern about using needles. Needle-free devices are effective injections for a wide range of drugs and are bioequivalent to needles. Advantages of needle-free delivery devices include less pain, fast injection, no needle disposal issue, and can be self-administered. Thus, the benefits of needle-free drug delivery devices over conventional needles and syringes are mainly responsible for the increasing demand for needle-free drug delivery devices.
Based on geography, the needle-free drug delivery device market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the global needle-free drug delivery device market. Asia Pacific is expected to register the highest CAGR in the needle-free drug delivery device market during 2022–2030.
Based on type, the needle-free drug delivery devices market is segmented into inhalers, jet injectors, novel needles, transdermal patches, and others. By application, the market is segmented into insulin delivery, vaccination, pain management, and others. The insulin delivery disease segment dominated the market in 2023.
Increasing prevalence of chronic diseases and increasing needlestick injuries propels the needle-free drug delivery devices market growth. However, the high cost of development as compare to injections hinders the growth of the market.